 |
|
|
| |
Antiviral activity of JNJ-4964 (AL-034/TQ-A3334),a selective Toll-Like Receptor 7 agonist, after oral administration for 12 weeks in AAV/HBV mice
|
| |
| |
Reported by Jules Levin
EASL 2019 April 10-14 Vienna
Florence Herschke1, Chris Li2, Ren Zhu2, Qinglin Han2, Qing Lu2, Erio Barale1, Sandra De Jonghe1, Tse-I Lin3,An De Creus1
1Janssen PharmaceuticaNV, Beerse, Belgium
2Janssen China R&D Center, Shanghai, China
3Formerly Janssen Biopharma (a Janssen Pharmaceuticals company), San Francisco, USA
|
| |
|
|
|
|
|
